Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Gene Ther
2020 Feb 01; doi: 10.1038/s41434-019-0071-x.
Show Gene links
Show Anatomy links
Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth.
Tamura RE
,
Lana MG
,
Costanzi-Strauss E
,
Strauss BE
.
???displayArticle.abstract???
For patients with metastatic prostate cancer, the 5-year survival rate of 31% points to a need for novel therapies and improvement of existing modalities. We propose that p53 gene therapy and chemotherapy, when combined, will provide superior tumor cell killing for the treatment of prostate carcinoma. To this end, we have developed the AdRGD-PGp53 vector which offers autoregulated expression of p53, resulting in enhanced tumor cell killing in vitro and in vivo. Here, we combined AdRGD-PGp53 along with the chemotherapy drugs used in the clinical treatment of prostate carcinoma, mitoxantrone, docetaxel, or cabazitaxel. Our results indicate that all drugs increase phosphorylation of p53, leading to improved induction of p53 targets. In vitro experiments reveal that AdRGD-PGp53 sensitizes prostate cancer cells to each of the drugs tested, conferring increased levels of cell death. In a xenograft mouse model of in situ gene therapy, AdRGD-PGp53 treatment, when combined with cabazitaxel, drastically reduced tumor progression and increased survival rates to 100%. Strikingly, we used a sub-therapeutic dose of cabazitaxel thus avoiding leukopenia, yet still showed potent anti-tumor effects when combined with AdRGD-PGp53 in this mouse model. The AdRGD-PGp53 approach warrants further development for its application in gene therapy of prostate carcinoma.
Bajgelman,
Development of an adenoviral vector with robust expression driven by p53.
2008, Pubmed
Bajgelman,
Development of an adenoviral vector with robust expression driven by p53.
2008,
Pubmed
Bajgelman,
AAVPG: a vigilant vector where transgene expression is induced by p53.
2013,
Pubmed
Berry,
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.
2002,
Pubmed
Cisternino,
Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats.
2003,
Pubmed
Cowen,
Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy.
2000,
Pubmed
Debruyne,
Hormonal therapy of prostate cancer.
2002,
Pubmed
Eastham,
In vivo gene therapy with p53 or p21 adenovirus for prostate cancer.
1995,
Pubmed
Ernst,
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
2003,
Pubmed
Gan,
Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.
2011,
Pubmed
Gjerset,
Gene therapy approaches to sensitization of human prostate carcinoma to cisplatin by adenoviral expression of p53 and by antisense jun kinase oligonucleotide methods.
2001,
Pubmed
Guo,
Development of Gene Therapeutics for Head and Neck Cancer in China: From Bench to Bedside.
2018,
Pubmed
Haldar,
Bcl2 is the guardian of microtubule integrity.
1997,
Pubmed
Heidenreich,
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
2014,
Pubmed
Ko,
Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.
1996,
Pubmed
Liu,
DNA topoisomerase poisons as antitumor drugs.
1989,
Pubmed
Liu,
Functional p53 determines docetaxel sensitivity in prostate cancer cells.
2013,
Pubmed
Loughery,
Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters.
2014,
Pubmed
Maia,
A comprehensive review of immunotherapies in prostate cancer.
2017,
Pubmed
McCullough,
Sexual dysfunction after radical prostatectomy.
2005,
Pubmed
Merkel,
Combined p19Arf and interferon-beta gene transfer enhances cell death of B16 melanoma in vitro and in vivo.
2013,
Pubmed
Merkel,
Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6.
2010,
Pubmed
Nozawa,
Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer.
2015,
Pubmed
Osoba,
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.
1999,
Pubmed
Peng,
A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers.
2006,
Pubmed
Peng,
Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers.
2005,
Pubmed
Radhakrishnan,
Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
2010,
Pubmed
Ringel,
Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.
1991,
Pubmed
Sasaki,
Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells.
2001,
Pubmed
Schimming,
Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel.
1999,
Pubmed
Shieh,
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.
1997,
Pubmed
Siegel,
Cancer Statistics, 2017.
2017,
Pubmed
Strauss,
pCLPG: a p53-driven retroviral system.
2004,
Pubmed
Tamura,
Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy.
2016,
Pubmed
Tamura,
Induction of Oxidants Distinguishes Susceptibility of Prostate Carcinoma Cell Lines to p53 Gene Transfer Mediated by an Improved Adenoviral Vector.
2017,
Pubmed
Tannock,
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1996,
Pubmed
Tannock,
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
2004,
Pubmed
Tomayko,
Determination of subcutaneous tumor size in athymic (nude) mice.
1989,
Pubmed
de Bono,
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
2010,
Pubmed
